[Sequential autoimmunity? The rare case of MDA5 dermatomyositis and sarcoidosis].

Z Rheumatol

Sektion für Rheumatologie und Entzündliche Systemerkrankungen in der III. Medizin, Universitätsklinikum Hamburg-Eppendorf (UKE), Martinistr. 52, 20246, Hamburg, Deutschland.

Published: February 2025

Background: Anti-MDA5 positive dermatomyositis is a rare subtype of idiopathic inflammatory myopathies often accompanied by rapidly progressive interstitial lung disease and severe cutaneous ulcerations. It is associated with a high mortality. The simultaneous occurrence of sarcoidosis with multisystemic involvement of myositis has only been described very rarely in the literature to date.

Case Report: We report the case of a 39-year-old man with a 3-year history of anti-MDA‑5 positive dermatomyositis who developed a worsening of dyspnea and hypercalcemia with acute kidney injury and a marked deterioration in his general condition after successive reductions in immunosuppressive therapy. A bronchoscopy and lymph node biopsy ultimately confirmed the diagnosis of sarcoidosis.

Conclusion: This case report illustrates the importance of continuously re-evaluating the diagnosis when new symptoms occur during the course of a rare disease. In the presence of pronounced lymphadenopathy, new hypercalcemia and lung parenchymal changes atypical for dermatomyositis, the differential diagnosis of sarcoidosis should also be considered.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00393-025-01627-xDOI Listing

Publication Analysis

Top Keywords

positive dermatomyositis
8
[sequential autoimmunity?
4
autoimmunity? rare
4
rare case
4
case mda5
4
dermatomyositis
4
mda5 dermatomyositis
4
dermatomyositis sarcoidosis]
4
sarcoidosis] background
4
background anti-mda5
4

Similar Publications

Based on the results of a multicenter phase II study of patients with previously treated thymic carcinoma, lenvatinib administration for unresectable thymic cancer has been covered under insurance in Japan since 2021. However, patients with interstitial lung disease (ILD) were excluded from that study; therefore, the efficacy and safety of lenvatinib in these patients remain unknown. Herein, we report the case of a woman in her 50s who was diagnosed with thymic carcinoma complicated with ILD.

View Article and Find Full Text PDF

Patients with dermatomyositis (DM) are particularly susceptible to the development of opportunistic infections due to immunosuppression induced by the disease itself and its treatment. We describe three patients who met the diagnostic criteria for DM and developed tuberculous myositis. The first case, a 54-year-old woman, had a positive polymerase chain reaction (PCR) for Mycobacterium tuberculosis detected in a post-mortem muscle biopsy.

View Article and Find Full Text PDF

Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by cutaneous lesions such as heliotrope rash, Gottron's papules, and Gottron's sign. Panniculitis is rarely reported as a skin manifestation of DM. Herein, we present a case of anti-nuclear matrix protein 2 antibody (NXP-2)-positive DM relapse with panniculitis in the absence of muscle symptoms.

View Article and Find Full Text PDF

Unlabelled: The aim of this study was to assess the 2017 EULAR/ACR classification criteria performance for determining idiopathic inflammatory myopathies (IIMs) in a cohort of patients with anti-MDA5 antibody-positive IIM-related interstitial lung disease (anti-MDA5+IIM-ILD). The outcomes of patients, who did not meet the EULAR/ACR criteria, and who had interstitial pneumonia and exhibited an autoimmune phenotype associated with anti-MDA5 positivity were also investigated.

Methods: This retrospective study recruited adult patients from four hospitals in China who were diagnosed with anti-MDA5 antibody-positive IIM-related interstitial lung disease.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!